Two separate clinical trials will go ahead on two artificial disc implants, following US Food and Drug Administration (FDA) approval.
The US developer of the implants, SpinalMotion, received conditional approvals from the FDA of two Investigational Device Exemption (IDE) applications. Under the IDEs, SpinalMotion will be able to start enrolment in the trials, one for its lumbar implant and one for its cervical disc implant. The implants are for treating patients with degenerative disc disease.
The company also said it secured US$20 million in funding from a range of investors.
The lumbar trial will involve 25 US sites in the first randomized study …
No comments:
Post a Comment